ORIGINAL ARTICLE FREE PREVIEW Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion Chunrong Tao, Raul G. Nogueira, Yuyou Zhu, et al N Engl J Med 2022; 387:1361-1372DOI: 10.1056/NEJMoa2206317 Abstract BACKGROUND Data from trials investigating the effects and risks of endovascular thrombectomy for the treatment of stroke due to basilar-artery occlusion are limited. METHODS We conducted a multicenter, prospective, randomized, controlled t...

CHEST INFECTIONS: ORIGINAL RESEARCH| VOLUME 162, ISSUE 4, P782-791, OCTOBER 01, 2022 Smartphone-Guided Self-prone Positioning vs Usual Care in Nonintubated Hospital Ward Patients With COVID-19: A Pragmatic Randomized Clinical Trial Garrett Rampon, Shijing Jia, Ritwick Agrawal, et al Chest 2022; 162: 782-791 Background Safe, effective, and easily implementable treatments that reduce the progression of respiratory failure in COVID-19 are urgent...

Original Investigation  October 26, 2022 Effect of Lower vs Higher Oxygen Saturation Targets on Survival to Hospital Discharge Among Patients Resuscitated After Out-of-Hospital Cardiac Arrest: The EXACT Randomized Clinical Trial Stephen A. Bernard, Janet E. Bray, Karen Smith, et al JAMA. Published online October 26, 2022. doi:10.1001/jama.2022.17701 Key Points Question  Among patients with return of spontaneous circulation after ...

Original Investigation  Caring for the Critically Ill Patient October 26, 2022 Association of Extracorporeal Membrane Oxygenation With New Mental Health Diagnoses in Adult Survivors of Critical Illness Shannon M. Fernando, Mary Scott, Robert Talarico, et al JAMA. Published online October 26, 2022. doi:10.1001/jama.2022.17714 Key Points Question  Is the use of extracorporeal membrane oxygenation (ECMO) associated with postdisch...

ARTICLES| VOLUME 10, ISSUE 10, P972-984, OCTOBER 01, 2022 Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group Lancet Respir Med 2022; 10: 972-984 Summary Background Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID...

ARTICLES| VOLUME 10, ISSUE 10, P985-996, OCTOBER 01, 2022 Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial Hugh Montgomery, F D Richard Hobbs, Francisco Padilla, et al Lancet Respir Med 2022; 10: 985-996 Summary Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal ant...

ORIGINAL ARTICLE Haloperidol for the Treatment of Delirium in ICU Patients Nina C. Andersen-Ranberg, Lone M. Poulsen, Anders Perner, et al N Engl J Med October 26, 2022DOI: 10.1056/NEJMoa2211868 Abstract BACKGROUND Haloperidol is frequently used to treat delirium in patients in the intensive care unit (ICU), but evidence of its effect is limited. METHODS In this multicenter, blinded, placebo-controlled trial, we randomly assigned adult patients wit...

ORIGINAL ARTICLE Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation Matthew W. Semler, Jonathan D. Casey, Bradley D. Lloyd, et al N Engl J Med October 24, 2022DOI: 10.1056/NEJMoa2208415 Abstract BACKGROUND Invasive mechanical ventilation in critically ill adults involves adjusting the fraction of inspired oxygen to maintain arterial oxygen saturation. The oxygen-saturation target that will optimize clinical outcomes in t...

ORIGINAL ARTICLE Early Active Mobilization during Mechanical Ventilation in the ICU The TEAM Study Investigators and the ANZICS Clinical Trials Group N Engl J Med October 26, 2022DOI: 10.1056/NEJMoa2209083 Abstract BACKGROUND Intensive care unit (ICU)–acquired weakness often develops in patients who are undergoing invasive mechanical ventilation. Early active mobilization may mitigate ICU-acquired weakness, increase survival, and reduce disability. ME...

Research Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study Jill M Ferdinands, Suchitra Rao, Brian E Dixon, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-072141 (Published 03 October 2022)Cite this as: BMJ 2022;379:e072141 Abstract Objective To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time ...